TY  - GEN
AU  - How,Jonathan
AU  - Minden,Mark D
AU  - Brian,Leber
AU  - Chen,Eric X
AU  - Brandwein,Joseph
AU  - Schuh,Andre C
AU  - Schimmer,Aaron D
AU  - Gupta,Vikas
AU  - Webster,Sheila
AU  - Degelder,Tammy
AU  - Haines,Patricia
AU  - Stayner,Lee-Anne
AU  - McGill,Shauna
AU  - Wang,Lisa
AU  - Piekarz,Richard
AU  - Wong,Tracy
AU  - Siu,Lillian L
AU  - Espinoza-Delgado,Igor
AU  - Holleran,Julianne L
AU  - Egorin,Merrill J
AU  - Yee,Karen W L
TI  - A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia
SN  - 1029-2403
PY  - 2016///0909
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - adverse effects
KW  - Azacitidine
KW  - administration & dosage
KW  - Decitabine
KW  - Drug Administration Schedule
KW  - Drug Resistance, Neoplasm
KW  - Female
KW  - Histone Deacetylase Inhibitors
KW  - Humans
KW  - Hydroxamic Acids
KW  - Leukemia, Myeloid, Acute
KW  - drug therapy
KW  - Male
KW  - Maximum Tolerated Dose
KW  - Middle Aged
KW  - Recurrence
KW  - Remission Induction
KW  - Retreatment
KW  - Treatment Outcome
KW  - Vorinostat
N1  - Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
UR  - https://doi.org/10.3109/10428194.2015.1018248
ER  -